Benzodiazepine and Z-Hypnotic Use in Pregnancy

What Did the BMJ Study on Benzodiazepines in Pregnancy Find?

The BMJ population-based cohort study drew on national health registries to follow children whose mothers were prescribed benzodiazepines (such as diazepam, lorazepam, or oxazepam) or Z-hypnotics (such as zolpidem and zopiclone) during pregnancy. By linking prescription records with later diagnoses of psychiatric disorders in childhood, researchers were able to estimate associations across a very large cohort, an approach that would not be feasible with a randomized trial for ethical reasons.

A key strength of the analysis was the use of sibling comparisons, in which exposed and unexposed children of the same mother were compared. This design helps account for stable maternal characteristics — including genetics, chronic mental health conditions, and socioeconomic factors — that could otherwise inflate apparent drug effects. When initial associations weaken in sibling analyses, it suggests that much of the observed risk reflects the underlying reason for prescribing rather than a direct pharmacological effect on the developing brain.

How Should Benzodiazepines and Z-Hypnotics Be Used During Pregnancy?

Benzodiazepines and Z-hypnotics are commonly prescribed for anxiety, panic disorders, and insomnia, but their use in pregnancy has long been a subject of caution. Regulatory bodies including the U.S. Food and Drug Administration and the European Medicines Agency advise that these medications cross the placenta and may be associated with neonatal effects such as sedation, withdrawal symptoms, and respiratory depression when used near delivery.

Clinical guidance from organizations such as the American College of Obstetricians and Gynecologists emphasizes that untreated maternal anxiety, insomnia, and severe psychiatric illness also carry risks for both mother and child. As a result, decisions about continuing, tapering, or switching these medications in pregnancy require individualized risk-benefit discussions, often involving obstetricians, psychiatrists, and primary care clinicians. Non-pharmacological treatments such as cognitive behavioral therapy for insomnia (CBT-I) and structured psychotherapy are typically considered first-line where feasible.

What Does This Mean for Pregnant Patients and Clinicians?

For pregnant patients already taking benzodiazepines or Z-hypnotics, abrupt discontinuation is generally discouraged because it can trigger withdrawal symptoms, rebound anxiety, or seizures. Instead, clinicians typically consider gradual tapering, switching to safer alternatives where possible, or maintaining treatment when the underlying condition would otherwise pose a serious risk. The BMJ study underscores that the decision is rarely about a single medication in isolation but about the entire clinical picture.

Public health implications include the need for better preconception counseling for women of reproductive age who are prescribed sedative-hypnotic medications, broader access to evidence-based non-drug treatments for insomnia and anxiety, and continued post-marketing surveillance using large registry datasets. Sibling-controlled designs like the one used here are increasingly considered a gold standard for evaluating medication safety in pregnancy when randomized trials are not possible.